Peroxisome proliferator-activated receptor-7 agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease

被引：67

作者：

Spears, M.

McSharry, C.

Thomson, N. C.

机构：

[1] Univ Glasgow, Dept Resp Med, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland

[2] Univ Glasgow, Dept Immunol, Div Immunol Infect & Inflammat, Glasgow G11 6NT, Lanark, Scotland

来源：

CLINICAL AND EXPERIMENTAL ALLERGY | 2006年 / 36卷 / 12期

关键词：

D O I：

10.1111/j.1365-2222.2006.02604.x

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Inhaled corticosteroids are the most effective therapy for chronic persistent asthma and have a role in the treatment of chronic obstructive pulmonary disease (COPD). However, corticosteroids have reduced efficacy in some patients with asthma and fail to halt the progressive deterioration in lung function characteristic of COPD. Additional or alternative drug treatments to corticosteroids are required to improve control of inflammation in patients with therapy resistant airway disease. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists have displayed potent anti-inflammatory properties in experimental models of asthma and other airway diseases and as a result have the potential to become an additional treatment for asthma and COPD. We review the evidence from these experimental models and their applicability to asthma and COPD and the requirements for future clinical and experimental research.

引用

页码：1494 / 1504

页数：11

共 108 条

[71]

Palakurthi SS, 2001, CANCER RES, V61, P6213

[72] A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ [J].